浏览全部资源
扫码关注微信
1.华中科技大学 同济医学院附属武汉儿童医院(武汉市妇幼保健院),武汉 430032
2.湖北中医药大学,武汉 430065
3.武汉市中西医结合医院,武汉市第一医院,武汉 430022
Received:08 April 2022,
Published Online:15 July 2022,
Published:20 October 2022
移动端阅览
张妍,向楠,周广文等.补肾化痰方调控去势骨质疏松大鼠骨脂分化改善绝经后骨丢失的机制[J].中国实验方剂学杂志,2022,28(20):53-60.
ZHANG Yan,XIANG Nan,ZHOU Guangwen,et al.Mechanism of Bushen Huatan Prescription in Regulation of Osteogenesis and Adipogenic Differentiation and Improvement of Postmenopausal Bone Loss in Ovariectomized Rats with Osteoporosis[J].Chinese Journal of Experimental Traditional Medical Formulae,2022,28(20):53-60.
张妍,向楠,周广文等.补肾化痰方调控去势骨质疏松大鼠骨脂分化改善绝经后骨丢失的机制[J].中国实验方剂学杂志,2022,28(20):53-60. DOI: 10.13422/j.cnki.syfjx.20221838.
ZHANG Yan,XIANG Nan,ZHOU Guangwen,et al.Mechanism of Bushen Huatan Prescription in Regulation of Osteogenesis and Adipogenic Differentiation and Improvement of Postmenopausal Bone Loss in Ovariectomized Rats with Osteoporosis[J].Chinese Journal of Experimental Traditional Medical Formulae,2022,28(20):53-60. DOI: 10.13422/j.cnki.syfjx.20221838.
目的
2
探讨补肾化痰方维持去势骨质疏松模型大鼠成骨/成脂分化平衡防治绝经后骨质疏松症(PMOP)的作用机制。
方法
2
6月龄雌性未孕SD大鼠75只,随机分为假手术组、模型组、阿托伐他汀组、利维爱组、补肾化痰组,除假手术组外,其余4组大鼠均切除双侧卵巢,假手术组切除卵巢周围相应体积的脂肪组织。术后第5周起给予对应药物灌胃,剂量分别为补肾化痰组9.4 g·kg
-1
、阿托伐他汀组0.92 mg·kg
-1
、利维爱组0.23 mg·kg
-1
,模型组和假手术组给予等容生理盐水,1次/d,持续8周。采用微计算机断层扫描技术(Micro CT)检测各组大鼠胫骨骨密度(BMD),苏木素-伊红(HE)染色观察各组大鼠骨髓脂肪组织(BMAT)相对面积,实时荧光定量聚合酶链式反应(Real-time PCR)、蛋白免疫印迹法(Western blot)检测骨组织Runt相关转录因子2(Runx2)、过氧化物酶体增殖物激活受体
γ
(PPAR
γ
)、瘦素(LPN)、瘦素受体(OBR)表达量。
结果
2
与假手术组比较,模型组大鼠BMD明显下降(
P
<
0.05),BMAT相对面积明显升高(
P
<
0.05),LPN、OBR、Runx2表达明显下降(
P
<
0.05),PPAR
γ
明显升高(
P
<
0.05)。与模型组比较,阿托伐他汀组、利维爱组、补肾化痰组BMD明显升高(
P
<
0.05),BMAT相对面积明显下降(
P
<
0.05),LPN、OBR、Runx2表达明显上升(
P
<
0.05),PPAR
γ
明显下降(
P
<
0.05)。
结论
2
补肾化痰方可能通过上调骨组织中LPN及OBR的表达,维持去势骨质疏松大鼠的骨脂分化平衡,从而减少绝经后骨丢失,发挥防治PMOP的作用。
Objective
2
To explore the underlying mechanism of Bushen Huatan prescription in alleviating postmenopausal osteoporosis (PMOP) by maintaining the balance of osteogenesis and adipogenic differentiation in ovariectomized rats with osteoporosis.
Method
2
Seventy-five 6-month-old non-pregnant female SD rats were randomly divided into sham-operation group, model group, atorvastatin group, liviol group, and Bushen Huatan prescription group. Bilateral ovaries were removed in the four groups except the sham-operation group, while only the same mass of adipose tissue around the ovaries was removed in the sham-operation group. On the 5
th
week after surgery, drugs were consecutively administrated for 8 weeks. Rats in the Bushen Huatan prescription group received 9.4 mg·kg
-1
of the prescription, rats in the atorvastatin group received 0.92 mg·kg
-1
of atorvastatin, rats in the Liviol group received 0.23 mg·kg
-1
of liviol, and rats in the model group and the sham-operation group received saline once a day. Micro-computed tomography (Micro CT) was used to detect bone mineral density (BMD) of rat tibia in each group. Hematoxylin-eosin (HE) staining was used to detect the relative area of rat bone marrow adipose tissue (BMAT) in each group. Real-time fluorescence quantitative polymerase chain reaction (Real-time PCR) and Western blot were used to detect the relative expression levels of Runt-related transcription factor 2 (Runx2), peroxisome proliferator-activated receptor (PPAR
γ
), leptin (LPN), and leptin receptor (OBR) in bone tissues.
Result
2
As compared with the sham operation group, the BMD of rats in the model group decreased (
P
<
0.05), while the relative area of BMAT increased (
P
<
0.05). In addition, the expression levels of LPN, OBR, and Runx2 decreased in the model group (
P
<
0.05), while the level of PPAR
γ
increased (
P
<
0.05). As compared with the model group, the BMD of rats in the atorvastatin group, the Livial group, and the Bushen Huatan prescription group increased (
P
<
0.05), and the relative area of BMAT decreased (
P
<
0.05). The expression levels of LPN, OBR, and Runx2 in these groups increased (
P
<
0.05), while the expression level of PPAR
γ
decreased (
P
<
0.05).
Conclusion
2
Bushen Huatan prescription plays the anti-osteoporosis role in the rat model of PMOP through up-regulating LPN and OBR in bone tissues and maintaining the balance of osteogenesis and adipogenic differentiation, thereby reducing postmenopausal bone loss and playing a role in the prevention and treatment of PMOP.
CONFERENCE C D . Diagnosis,prophylaxis and treatment of osteoporosis [J]. Am J Med , 1993 , 94 ( 6 ): 646 - 650 .
夏维波 , 章振林 , 林华 , 等 . 原发性骨质疏松症诊疗指南(2017) [J]. 中国骨质疏松杂志 , 2019 , 25 ( 3 ): 281 - 309 .
佚名 . 中国骨质疏松症流行病学调查及“健康骨骼”专项行动结果发布 [J]. 中华骨质疏松和骨矿盐疾病杂志 , 2019 , 12 ( 4 ): 317 - 318 .
白璧辉 , 谢兴文 , 李鼎鹏 , 等 . 我国近5年来骨质疏松症流行病学研究现状 [J]. 中国骨质疏松杂志 , 2018 , 24 ( 2 ): 253 - 258 .
祝晓雨 , 张伟光 , 赵志刚 . 骨质疏松症国内外药物治疗的研究现状 [J]. 中国临床药理学杂志 , 2020 , 36 ( 5 ): 588 - 592 .
史晓林 , 吴连国 , 刘康 . 绝经后骨质疏松症(骨痿)中医药诊疗指南(2019年版) [J]. 中医正骨 , 2020 , 32 ( 2 ): 1 - 13 .
TENCEROVA M , FERENCAKOVA M , KASSEM M . Bone marrow adipose tissue:Role in bone remodeling and energy metabolism [J]. Best Pract Res Clin Endocrinol Metab , 2021 , 35 ( 4 ): 101545 .
LI J , CHEN X , LU L , et al . The relationship between bone marrow adipose tissue and bone metabolism in postmenopausal osteoporosis [J]. Cytokine Growth Factor Rev , 2020 , 52 : 88 - 98 .
周亚娜 , 陈辉 , 向楠 . 补肾化痰法影响骨髓间充质干细胞成脂分化的实验研究 [J]. 时珍国医国药 , 2015 , 26 ( 10 ): 2325 - 2327 .
周亚娜 , 向楠 , 陈辉 . 补肾化痰法影响骨髓间充质干细胞成骨分化的实验研究 [J]. 中国中医基础医学杂志 , 2015 , 21 ( 3 ): 275 - 277 .
谭张奎 , 周广文 , 张妍 , 等 . 补肾化痰方基于白细胞介素-2/信号转导及转录启动子5通路改善去势大鼠骨代谢的作用机制 [J]. 中华中医药杂志 , 2021 , 36 ( 6 ): 3277 - 3282 .
李章青 , 向楠 , 周广文 , 等 . 补肾化痰方影响去势骨质疏松大鼠Leptin及 β 2 -AR表达的实验研究 [J]. 天津中医药 , 2020 , 37 ( 1 ): 87 - 92 .
张麟 , 向楠 , 周广文 , 等 . 补肾化痰方对去卵巢大鼠骨形成的影响及其作用机制研究 [J]. 中医正骨 , 2018 , 30 ( 10 ): 12 - 18 .
谭张奎 , 周广文 , 张妍 , 等 . 补肾化痰方对去势骨质疏松模型大鼠Th17/Treg平衡机制的影响 [J]. 中国实验方剂学杂志 , 2021 , 27 ( 5 ): 33 - 40 .
黄淑燕 . 补肾化痰方对去势骨质疏松大鼠OPG/RANKL/RANK通路影响的研究 [D]. 武汉 : 湖北中医药大学 , 2017 .
陈奇 . 中药药理研究方法学 . 2版 [M]. 北京 : 人民卫生出版社 , 2006 : 31 - 33
BEEKMAN K M , VELDHUIS-VLUG A G , VAN DER VEEN A , et al . The effect of PPAR γ inhibition on bone marrow adipose tissue and bone in C3H/HeJ mice [J]. Am J Physiol Endocrinol Metab , 2019 , 316 ( 1 ): E96 - E105 .
WEHRLI F W , HOPKINS J A , HWANG S N , et al . Cross-sectional study of osteopenia with quantitative MR imaging and bone densitometry [J]. Radiology , 2000 , 217 ( 2 ): 527 - 538 .
ROY B , CURTIS M E , FEARS L S , et al . Molecular mechanisms of obesity-induced osteoporosis and muscle atrophy [J]. Front Plant Sci , 2016 , 7 : 439 .
LIU J , ZHU L P , YANG X L , et al . HMG-CoA reductase inhibitors (statins) and bone mineral density:A Meta-analysis [J]. Bone , 2013 , 54 ( 1 ): 151 - 156 .
蔡晓燕 , 董光富 . 脂代谢及血清骨钙素水平与骨质疏松症的相关性分析 [J]. 中国骨质疏松杂志 , 2016 , doi: 10.3969/j.issn.1006-7108.2016.06.011 http://dx.doi.org/10.3969/j.issn.1006-7108.2016.06.011 .
孙建芝 , 牛晓亚 . 痰浊证微观辨证指标的实验研究 [J]. 河南中医 , 1996 , 16 ( 2 ): 2 .
徐众华 , 莫雨晴 , 周驰 . 基于BMP/Runx2/Osx信号通路研究淫羊藿总黄酮改善绝经后骨质疏松模型大鼠的作用机制 [J]. 中国药房 , 2020 , 31 ( 19 ): 2333 - 2338 .
陈露华 , 唐宏宇 . 补骨脂素对绝经后大鼠骨质疏松及PI3K/Akt/mTOR信号通路的影响 [J]. 中国药房 , 2021 , 32 ( 6 ): 697 - 701 .
赵素霞 , 刘会丽 , 江红 . 菟丝子黄酮通过调节Wnt/ β -catenin信号通路干预去卵巢大鼠骨代谢的机制研究 [J]. 临床和实验医学杂志 , 2018 , 17 ( 1 ): 25 - 28 .
贺立勍 . 瓜蒌、薤白降脂作用的析因研究 [J]. 湖南中医药导报 , 2002 , doi: 10.13862/j.cnki.cn43-1446/r.2002.04.040 http://dx.doi.org/10.13862/j.cnki.cn43-1446/r.2002.04.040 .
王林海 , 卢健棋 , 黄舒培 , 等 . 中医药治疗血脂异常的研究进展 [J]. 中华中医药学刊 , 2018 , 36 ( 1 ): 106 - 109 .
李丹 , 董开心 , 刘燕华 , 等 . 降脂类中药降脂成分及降脂机制的研究进展 [J]. 江西医药 , 2020 , 55 ( 11 ): 1736 - 1740 .
冷明昊 , 张卫华 , 陈东 , 等 . 红曲通过启动腺甘酸活化蛋白激酶上调骨形态发生蛋白2表达对去卵巢大鼠骨质疏松症的改善作用 [J]. 中国中医骨伤科杂志 , 2021 , 29 ( 3 ): 7 - 11 .
魏占英 , 章振林 . Micro-CT在骨代谢研究中骨微结构指标的解读及应用价值 [J]. 中华骨质疏松和骨矿盐疾病杂志 , 2018 , 11 ( 2 ): 6 .
李延红 , 党晓谦 , 龚福太 , 等 . 骨质疏松动物模型的研究进展及文献回顾 [J]. 中国组织工程研究 , 2018 , 22 ( 12 ): 6 .
梁克玉 , 邓小川 , 何承建 . 骨质疏松症 [M]. 湖北科学技术出版社 . 2013 : 46 .
HERRMANN M . Marrow fat-secreted factors as biomarkers for osteoporosis [J]. Curr Osteoporos Rep , 2019 , 17 ( 6 ): 429 - 437 .
张玲莉 , 雷乐 , 吴伟 . MAPK信号通路在骨髓间充质干细胞向成骨细胞分化中的作用 [J]. 中华骨质疏松和骨矿盐疾病杂志 , 2021 , 14 ( 1 ): 75 - 81 .
JAMES A W . Review of signaling pathways governing MSC osteogenic and adipogenic differentiation [J]. Scientifica , 2013 , doi: 10.1155/2013/684736 http://dx.doi.org/10.1155/2013/684736 .
BUKOWSKA J , FRAZIER T , SMITH S , et al . Bone marrow adipocyte developmental origin and biology [J]. Curr Osteoporos Rep , 2018 , 16 ( 3 ): 312 - 319 .
胡衍 , 陈晓 , 苏佳灿 . 重视骨髓脂肪组织在骨质疏松性骨折愈合中的调控作用 [J]. 中华创伤杂志 , 2021 , 37 ( 11 ): 968 - 972 .
陈琼 , 王亮 . 微循环与骨质疏松的关系 [J]. 中国骨质疏松杂志 , 2017 , 23 ( 8 ): 1086 - 1089,1099 .
LI J , CHEN X , LU L , et al . The relationship between bone marrow adipose tissue and bone metabolism in postmenopausal osteoporosis [J]. Cytokine Growth Factor Rev , 2020 , 52 : 88 - 98 .
周鑫 , 赵佳佳 , 陈莉莉 . 调节骨髓间充质干细胞成骨成脂分化的因素 [J]. 中国组织工程研究 , 2017 , 21 ( 17 ): 2759 - 2765 .
ZHANG L , SU P , XU C , et al . Melatonin inhibits adipogenesis and enhances osteogenesis of human mesenchymal stem cells by suppressing PPAR γ expression and enhancing Runx2 expression [J]. J Pineal Res , 2010 , 49 ( 4 ): 364 - 372 .
李智奎 , 孔俊博 , 赵王林 . 淫羊藿苷调控Wnt/ β -catenin信号通路干预大鼠MSCs成脂成骨双向分化实验研究 [J]. 中国免疫学杂志 , 2019 , 35 ( 24 ): 2985 - 2990 .
MURUGANANDAN S , ROMAN A A , SINAL C J . Adipocyte differentiation of bone marrow-derived mesenchymal stem cells:Cross talk with the osteoblastogenic program [J]. Cell Mol Life Sci , 2009 , 66 ( 2 ): 236 - 253 .
MARGETIC S , GAZZOLA C , PEGG G G , et al . Leptin:A review of its peripheral actions and interactions [J]. Int J Obes , 2002 , 26 ( 11 ): 1407 - 1433 .
TRINH T , BROXMEYER H E . Role for leptin and leptin receptors in stem cells during health and diseases [J]. Stem Cell Rev Rep , 2021 , 17 ( 2 ): 511 - 522 .
UPADHYAY J , FARR O M , MANTZOROS C S . The role of leptin in regulating bone metabolism [J]. Metabolism , 2015 , 64 ( 1 ): 105 - 113 .
COEN G . Leptin and bone metabolism [J]. J Nephrol , 2004 , 17 ( 2 ): 187 - 189 .
何琪 , 杨均政 , 张罡瑜 , 等 . 通过Micro-CT评价瘦素受体缺乏的2型糖尿病小鼠四肢骨的骨代谢变化 [J]. 中国骨质疏松杂志 , 2021 , 27 ( 4 ): 492 - 497 .
HAMRICK M W , FERRARI S L . Leptin and the sympathetic connection of fat to bone [J]. Osteoporosis Int , 2008 , 19 ( 7 ): 905 - 912 .
THOMAS T , GORI F , KHOSLA S , et al . Leptin acts on human marrow stromal cells to enhance differentiation to osteoblasts and to inhibit differentiation to adipocytes [J]. Endocrinology , 1999 , 140 ( 4 ): 1630 - 1638 .
THOMAS T , BURGUERA B . Is leptin the link between fat and bone mass? [J]. J Bone Miner Res , 2002 , 17 ( 9 ): 1563 - 1569 .
BARTELL S M , RAYALAM S , AMBATI S , et al . Central (ICV) leptin injection increases bone formation,bone mineral density,muscle mass,serum IGF‐1,and the expression of osteogenic genes in leptin‐deficient ob/ob mice [J]. J Bone Miner Res , 2011 , 26 ( 8 ): 1710 - 1720 .
0
Views
21
下载量
5
CSCD
Publicity Resources
Related Articles
Related Author
Related Institution